Drug-induced cardiotoxicity is one of the major causes of post-market withdrawal of drugs. Therefore, the prediction of cardiac adverse effects early in drug development would accelerate the process of developing safe drugs and reduce the associated costs. Moreover, a better understanding of mechanisms underlying drug-induced cardiotoxicity during therapies, such as cancer therapy, also known as cardio-oncology would help clinicians for better management of patients who develop cardiovascular diseases as a result of the toxic side effects of anti-cancer drugs. In this direction, we aim to develop a hiPSC-CMs/organoids platform for precise drug testing and cardio-oncology studies.